Healthcare Stocks Touched New Lows: VIVUS (NASDAQ:VVUS), Akebia Therapeutics Inc (NASDAQ:AKBA), Versartis Inc (NASDAQ:VSAR), BioLife Solutions (NASDAQ:BLFS)

VIVUS Inc. (NASDAQ:VVUS) lower following news late Tuesday night that three directors — J. Martin Carroll, Mark B. Logan and Robert N. Wilson — will not stand for re-election to the company’s Board. This will be the sixth-straight session for the stock to close lower. VIVUS, Inc. (NASDAQ:VVUS) stock performance was 0.20% in last session and finished the day at $5.00. Traded volume was 2.64million shares in the last session and the average volume of the stock remained 3.38million shares. The beta of the stock remained 1.32. VIVUS, Inc. (NASDAQ:VVUS) insider ownership is 0.10%.

Angel capital investing, the ground-floor base for building a startup company that could become the next Google or at least the next Akebia Therapeutics Inc (NASDAQ:AKBA), is on the rise in Ohio and its neighboring states. Akebia Therapeutics Inc (NASDAQ:AKBA) rose 3.17 percent to $18.89 Wednesday on volume of 158,822.00million shares. The intra-day range of the stock was $16.41 to $18.99. Akebia Therapeutics Inc (NASDAQ:AKBA) has a market capitalization of $366.14million.

Versartis Inc. (NASDAQ:VSAR), was the top U.S. priced IPO near the end of the quarter at $21 a share – the high end of a range – to raise $126 million. Versartis Inc (NASDAQ:VSAR)’s stock on Apr 09, 2014 reported a increase of 0.94% to the closing price of $28.00. Its fifty two weeks range is $26.51 -$36.30. The total market capitalization recorded $676.61million. The overall volume in the last trading session was 110,579.00million shares. In its share capital, VSAR has 24.16million outstanding shares.

The Street Ratings upgraded Bio-Rad from hold to buy. The company’s strengths are: its revenue growth, largely solid financial position with reasonable debt levels, reasonable valuation levels, expanding profit margins and increase in stock price during the past year. On Wednesday, shares of BioLife Solutions Inc (NASDAQ:BLFS) dropped -1.76% to close the day at $3.35. Company return on investment (ROI) is 11.10% and its monthly performance is recorded as -41.74%. BioLife Solutions Inc (NASDAQ:BLFS) quarterly revenue growth is -60.12%.